Recombinant Zoster Vaccine not checked
MAXVAX Biotechnology Limited Liability Company
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection”In the company’s words, NCT06447779 on ClinicalTrials.gov
- Tested for
- Herpes Zoster (2 trials)
- Main trialPhase 3
- “The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.”In the company’s words, NCT06447779 on ClinicalTrials.gov
Other drugs for Herpes Zoster
- HZ/su vaccineGSK · Phase 3
- CVI-VZV-001Aribio Lab Co., Ltd. · Phase 2
- SYS6017CSPC · Phase 2
- Z-1018Dynavax Technologies Corporation · Phase 1/2
- SYS6052CSPC · Phase 1/2
- HZ VaccineShenzhen Shenxin Biotechnology Co., Ltd · Phase 2
Coming up1
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 29 Mar 2026 | Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older | |
| Phase 3Active, not recruiting | 31 Dec 2027 | A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) | |
| Phase 3Completed | 9 May 2025 | Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026